IP Verse

Ophthalmic Suspension Composition - EP3721868

The patent EP3721868 was granted to Bausch & Lomb Incorporated on Sep 3, 2025. The application was originally filed on Jan 26, 2016 under application number EP20166312A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3721868

BAUSCH & LOMB INCORPORATED
Application Number
EP20166312A
Filing Date
Jan 26, 2016
Status
Patent Maintained As Amended
Aug 1, 2025
Grant Date
Sep 3, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZFeb 28, 2023KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS4540930
DESCRIPTIONUS4615697
DESCRIPTIONUS4996335
DESCRIPTIONUS5192535
DESCRIPTIONUS5538721
DESCRIPTIONWO8906964
OPPOSITIONWO2013043387
OPPOSITIONWO2013169647
OTHERAU2015288643
OTHERUS2010226997
OTHERUS7001615
OTHERWO2013169647
OTHERWO2015105652
OTHERWO2016006701
OTHERWO2016016908
SEARCHEP0659433
SEARCHUS2013303502
SEARCHUS2014328917
SEARCHWO2004006959
SEARCHWO2013043387

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- SCHOENWALD RDHARRIS RGTURNER D et al., "Ophthalmic bioequivalence of steroid/antibiotic combination formulations", Biopharm Drug Dispos., (19870000), vol. 8, pages 527 - 548-
DESCRIPTION- TANG-LIU DDBURKE PJ., "The effect of azone on ocular levobunolol absorption: calculating the area under the curve and its standard error using tissue sampling compartments", Pharm Res., (19880000), vol. 5, pages 238 - 241-
DESCRIPTION- LIU et al., "Nanosuspensions of poorly soluble drugs: preparation and development by wet milling", Int. J. of Pharm, (20110000), vol. 411, no. 1-2, doi:10.1016/j.ijpharm.2011.03.050, pages 215 - 222, XP055143914
OPPOSITION- Abdulganee Memon et al, "Optimization of Formulation Parameters on Ocular Loteprednol Etabonate Nanosuspension by Media Milling Method", International Journal of Pharmaceutical & Biological Archives, (20120101), vol. 4, no. 1, ISSN 0976-3333, pages 46 - 51, XP055643061-
OPPOSITION- Anonymous, "Results positive for B+L sub-micron gel formulation of loteprednol etabonate", Ophthalmology Times, (20140930), Ophthalmology Times, URL: https://www.ophthalmologytimes.com/modern-medicine-feature-articles/results-positive-bl-sub-micron-gel-formulation-loteprednol-etabonate, (20191107), XP055639922-
OPPOSITION- Gourav Rajoria, Gupta Arushi, "In-Situ Gelling System: A Novel Approach for Ocular Drug Delivery", American Journal of PharmTech Research, (20120101), vol. 2, no. 4, ISSN 2249-3387, pages 24 - 53, XP055643055-
OPPOSITION- Prasanna Lakshmi, Giddam Ashwini Kumar, "NANO­-SUSPENSION TECHNOLOGY: A REVIEW", International Journal of Pharmacy and Pharmaceutical Sciences, (20100101), vol. 2, no. Suppl.4, pages 35 - 40, XP055643057-
OPPOSITION- Rowe Raymond C, Sheskey Paul J, Marian E. Quinn, "Carbomer. Hypromellose. Polycarbophil", Handbook of Pharmaceutical Excipients, Pharmaceutical Press, (20090101), pages 110 - 509-512, XP093031841-
OPPOSITION- Sepassi S. et al, "Effect of Polymer Molecular Weight on the Production of Drug Nanoparticles", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (20071001), vol. 96, no. 10, doi:10.1002/jps.20979, ISSN 0022-3549, pages 2655 - 2666, XP093031654
OPPOSITION- Lisa Schopf et al, "Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation", Ophthalmology and Therapy, (20141201), vol. 3, no. 1-2, doi:10.1007/s40123-014-0021-z, ISSN 2193-8245, pages 63 - 72, XP055643059
OPPOSITION- Martin J Coffey et al, "Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop", Clinical Ophthalmology, (20130101), vol. 7, doi:10.2147/OPTH.S40588, pages 299 - 312, XP055643072

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents